Mentice AB (publ) (MNTC.ST)
SEK 25.3
(1.61%)
SEK 25.3
(1.61%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 237.06 Million SEK | 10.13% |
| 2022 | 215.26 Million SEK | 23.15% |
| 2021 | 174.79 Million SEK | 28.81% |
| 2020 | 135.69 Million SEK | -12.26% |
| 2019 | 154.65 Million SEK | 28.66% |
| 2018 | 120.2 Million SEK | 39.85% |
| 2017 | 85.95 Million SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 68.81 Million SEK | 2.66% |
| 2024 Q1 | 67.03 Million SEK | 7.49% |
| 2023 Q2 | 61.57 Million SEK | 9.09% |
| 2023 Q1 | 56.43 Million SEK | 2.7% |
| 2023 FY | 237.06 Million SEK | 10.13% |
| 2023 Q4 | 62.35 Million SEK | 10.0% |
| 2023 Q3 | 56.69 Million SEK | -7.93% |
| 2022 Q2 | 56.58 Million SEK | 12.68% |
| 2022 Q1 | 50.21 Million SEK | -4.69% |
| 2022 FY | 215.26 Million SEK | 23.15% |
| 2022 Q4 | 54.95 Million SEK | 2.71% |
| 2022 Q3 | 53.5 Million SEK | -5.44% |
| 2021 Q1 | 39.93 Million SEK | 5.42% |
| 2021 Q2 | 42.11 Million SEK | 5.46% |
| 2021 Q4 | 52.68 Million SEK | 31.0% |
| 2021 Q3 | 40.21 Million SEK | -4.51% |
| 2021 FY | 174.79 Million SEK | 28.81% |
| 2020 Q4 | 37.88 Million SEK | 28.19% |
| 2020 Q3 | 29.55 Million SEK | -11.44% |
| 2020 Q2 | 33.36 Million SEK | -7.6% |
| 2020 Q1 | 36.11 Million SEK | -12.01% |
| 2020 FY | 135.69 Million SEK | -12.26% |
| 2019 FY | 154.65 Million SEK | 28.66% |
| 2019 Q4 | 41.04 Million SEK | 8.65% |
| 2019 Q3 | 37.77 Million SEK | -5.66% |
| 2019 Q2 | 40.04 Million SEK | 11.87% |
| 2019 Q1 | 35.79 Million SEK | 14.38% |
| 2018 Q2 | 31.99 Million SEK | 16.33% |
| 2018 Q3 | 29.61 Million SEK | -7.45% |
| 2018 Q4 | 31.29 Million SEK | 5.68% |
| 2018 FY | 120.2 Million SEK | 39.85% |
| 2018 Q1 | 27.5 Million SEK | 0.0% |
| 2017 FY | 85.95 Million SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Acarix AB (publ) | 82.85 Million SEK | -186.132% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 61.252% |
| ADDvise Group AB (publ) | 611.8 Million SEK | 61.252% |
| Arcoma AB | 53.25 Million SEK | -345.166% |
| Bactiguard Holding AB (publ) | 4.96 Million SEK | -4670.779% |
| BICO Group AB (publ) | 2.84 Billion SEK | 91.677% |
| Boule Diagnostics AB (publ) | 210.44 Million SEK | -12.648% |
| CellaVision AB (publ) | 295.99 Million SEK | 19.909% |
| Clinical Laserthermia Systems AB (publ) | 68.93 Million SEK | -243.914% |
| Chordate Medical Holding AB (publ) | 1.3 Million SEK | -18007.476% |
| C-Rad AB (publ) | 3.8 Million SEK | -6138.421% |
| Duearity AB (publ) | 21.58 Million SEK | -998.263% |
| Dignitana AB (publ) | 74.73 Million SEK | -217.197% |
| Episurf Medical AB (publ) | 2.7 Million SEK | -8680.0% |
| Getinge AB (publ) | 10.75 Billion SEK | 97.797% |
| Scandinavian Real Heart AB (Publ) | 18.22 Million SEK | -1200.487% |
| Iconovo AB (publ) | 63.35 Million SEK | -274.181% |
| Integrum AB (publ) | 90.57 Million SEK | -161.738% |
| Luxbright AB (publ) | 23.09 Million SEK | -926.655% |
| OssDsign AB (publ) | 175.6 Million SEK | -34.999% |
| Paxman AB (publ) | 133.8 Million SEK | -77.175% |
| Promimic AB (publ) | 48.55 Million SEK | -388.26% |
| Qlife Holding AB (publ) | 162.38 Million SEK | -45.986% |
| SciBase Holding AB (publ) | 69.97 Million SEK | -238.773% |
| ScandiDos AB (publ) | 61.03 Million SEK | -288.381% |
| Sectra AB (publ) | 39.06 Million SEK | -506.866% |
| Sedana Medical AB (publ) | 174.52 Million SEK | -35.829% |
| Senzime AB (publ) | 141.51 Million SEK | -67.513% |
| SpectraCure AB (publ) | 12.12 Million SEK | -1854.65% |
| Stille AB | 87.21 Million SEK | -171.799% |
| Vitrolife AB (publ) | 5.56 Billion SEK | 95.742% |
| Xvivo Perfusion AB (publ) | 440.92 Million SEK | 46.236% |